- Home
- REFI vs CLLS Comparison
REFI vs CLLS Comparison
Compare REFI & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REFI
- CLLS
- Stock Information
- Founded
- REFI 2021
- CLLS 1999
- Country
- REFI United States
- CLLS France
- Employees
- REFI N/A
- CLLS N/A
- Industry
- REFI Real Estate Investment Trusts
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- REFI Real Estate
- CLLS Health Care
- Exchange
- REFI Nasdaq
- CLLS Nasdaq
- Market Cap
- REFI 255.6M
- CLLS 299.0M
- IPO Year
- REFI 2021
- CLLS 2007
- Fundamental
- Price
- REFI $12.85
- CLLS $3.49
- Analyst Decision
- REFI Strong Buy
- CLLS Buy
- Analyst Count
- REFI 3
- CLLS 1
- Target Price
- REFI $20.00
- CLLS $8.00
- AVG Volume (30 Days)
- REFI 137.6K
- CLLS 186.3K
- Earning Date
- REFI 11-04-2025
- CLLS 11-03-2025
- Dividend Yield
- REFI 15.94%
- CLLS N/A
- EPS Growth
- REFI N/A
- CLLS N/A
- EPS
- REFI 1.84
- CLLS N/A
- Revenue
- REFI $56,608,781.00
- CLLS $63,438,000.00
- Revenue This Year
- REFI $11.43
- CLLS N/A
- Revenue Next Year
- REFI $4.75
- CLLS $66.76
- P/E Ratio
- REFI $7.03
- CLLS N/A
- Revenue Growth
- REFI 2.58
- CLLS 223.09
- 52 Week Low
- REFI $12.00
- CLLS $1.10
- 52 Week High
- REFI $16.29
- CLLS $5.48
- Technical
- Relative Strength Index (RSI)
- REFI 45.34
- CLLS 46.96
- Support Level
- REFI $12.87
- CLLS $3.43
- Resistance Level
- REFI $13.24
- CLLS $3.79
- Average True Range (ATR)
- REFI 0.21
- CLLS 0.31
- MACD
- REFI 0.05
- CLLS -0.09
- Stochastic Oscillator
- REFI 61.29
- CLLS 4.60
About REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.